Convergence Lab Director Charlotte Kuperwasser’s new study reveals underlying molecular mechanisms that drive malignancy and aggressiveness in basal-like breast cancer

Silencing SIRT2, a member of the sirtuin family of enzymes, reduces the invasiveness of basal-like breast cancer cells in culture and inhibits tumor growth in mice, according to new research led by scientists from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts in Boston. The absence of SIRT2 appears to accelerate the degradation of Slug, a transcription factor that has previously been implicated in tumor progression and metastasis.

The findings, published online in Cell Reports on Oct. 25, reveal underlying molecular mechanisms and potential new approaches to treat one of the deadliest breast cancer subtypes.

Read article